查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914577

人類胰島素市場－全球產業規模、佔有率、趨勢、機會及預測（依適應症、品牌、給藥途徑、類型、起效時間、產品、地區及競爭格局分類），2021-2031年

Human Insulin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球人類胰島素市場預計將從2025年的248.1億美元成長到2031年的383.1億美元，複合年成長率（CAGR）為7.51%。該市場涵蓋了與內源性胰島素結構相同的生物合成肽激素的商業領域，這些激素是調節糖尿病患者血糖值的關鍵手段。市場成長的主要促進因素是全球糖尿病盛行率的不斷上升，都市化、人口老化和肥胖率的上升進一步加劇了這一趨勢。這些因素使得持續的治療管理變得至關重要。根據國際糖尿病聯盟（IDF）2024年發布的報告，全球約有5.89億成年人患有糖尿病，凸顯了龐大的患者群體對有效醫療解決方案的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 248.1億美元
市場規模：2031年 383.1億美元
複合年成長率：2026-2031年 7.51%
成長最快的細分市場 生物相似藥
最大的市場 北美洲

阻礙市場擴張的一大挑戰是高昂的生產和分銷成本，這限制了開發中國家對產品的可近性。這些經濟障礙往往會降低患者的用藥依從性，並限制疾病盛行率成長最快地區的市場滲透率。因此，這些地區嚴格的定價限制加上不完善的報銷體系，成為胰島素廣泛應用的主要瓶頸，並限制了潛在的收入成長。

市場促進因素

胰島素輸注系統的技術進步正在改變患者照護，人們的偏好正從傳統的管瓶和注射器轉向自動化、微創設備。智慧胰島素筆、無導管胰島素幫浦和閉合迴路系統等創新技術，結合持續血糖監測，顯著改善了血糖控制和治療順從性。這項變革的驅動力在於對先進平台日益成長的需求，這些平台能夠實現精準給藥，並將對患者生活的影響降至最低。例如，Insulet公司在2024年11月公佈的2024年第三季財務業績中報告稱，其Omnipod胰島素管理系統的營收年增約26%。這主要得益於該系統在第1型和第2型糖尿病領域的強勁應用，顯示這些滿足治療需求的技術正在推動市場成長。

同時，經濟實惠的生物相似藥的日益普及正在消除經濟壁壘，並改變競爭格局。隨著關鍵胰島素類似物的專利到期，高品質生物相似藥的出現為患者和醫療保健系統節省了大量成本，尤其是在新興市場，可負擔性是這些市場的首要考慮因素。這一趨勢正在推動治療的可及性和使用量的增加。例如，百康公司（Biocon Limited）於2024年10月公佈了其2025會計年度第二季合併會計，報告稱其生物相似藥業務的銷售額同比成長19%（以可比口徑計算）。此外，國際糖尿病聯盟（IDF）預計，到2024年，全球與糖尿病相關的醫療保健支出將超過1兆美元，因此，對經濟實惠的解決方案的迫切需求將繼續推動市場擴張和永續的醫療保健支出。

市場挑戰

生產和分銷相關的高昂成本是限制全球人類胰島素市場成長的主要結構性障礙，尤其是在開發中國家。生物合成胜肽激素的生產需要嚴格的品管和複雜、資本密集的生物技術設施，導致成品基準居高不下。此外，在整個分銷過程中維持嚴格的低溫運輸物流要求也帶來了巨大的額外成本，進一步推高了終端用戶的價格。在平均收入較低、醫療基礎設施有限的地區，這些累積成本使得很大一部分人群無力承擔這種治療方法，從而有效地限制了市場滲透率。

這種經濟差距嚴重限制了市場潛力，因為需求成長最快的地區往往也是經濟限制最嚴重的地區。根據國際糖尿病聯盟（IDF）的數據，到2024年，超過75%的糖尿病患者將居住在中低收入國家。這項數據凸顯了挑戰的嚴峻性，因為絕大多數潛在患者居住在當前價格體系下難以獲得治療的地區。因此，由於關鍵成長領域缺乏必要的治療，市場成長面臨瓶頸，收入成長也受到限制。

市場趨勢

每週一次基礎胰島素製劑的推出從根本上改變了治療模式，減輕了每日注射帶來的負擔。藥廠正致力於研發能夠維持血糖穩定7天的超長效胰島素類似物，旨在減少注射疲勞，並提高第2型糖尿病患者的長期用藥遵從性。這項創新透過化學技術的進步而非簡單的器械改進來解決生活方式方面的限制。例如，禮來公司於2024年9月報告稱，其III期QWINT-2試驗表明，每週一次的胰島素Efcitra alfa在療效上不劣於每日一次的胰島素degludec，在未接受過胰島素治療的成年患者中，Efcitra alfa可使HbA1c水平降低1.34%（degludec組降低1.34%。

同時，致力於研發非侵入性口服胰島素給藥系統的公司持續投入巨資，以期徹底消除皮下注射的必要性。這一趨勢包括對旨在耐受胃溶的膠囊化口服製劑進行持續的臨床研究，這種製劑有望透過提供無針注射方案，顯著提高胰島素治療的早期應用率。儘管過去面臨一些臨床挑戰，但由於該技術有望提高患者的便利性並克服注射治療的心理障礙，因此仍被積極推進。作為這些持續努力的一部分，Oramed Pharmaceuticals公司於2024年2月宣布計劃重啟其口服胰島素候選藥物ORMD-0801的3期臨床試驗。該試驗將針對在領先數據分析中顯示出顯著療效的特定患者亞群。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球人類胰島素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依適應症（1 型糖尿病、2 型糖尿病）
    • 依品牌（來得時、優泌林 R、諾和靈 R、優泌林 N、Exuberata、Afrezza、諾和靈 N）
    • 依給藥途徑（皮下、經皮、鼻腔、靜脈、口服、其他）
    • 依類型（長效、加強型、複方、生物相似藥、傳統藥）
    • 依起效時間分類（速效、短效、中效、長效、預混合料、吸入、超長效）
    • 依產品分類（胰島素筆、胰島素幫浦、輸液系統、注射）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美人胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲人胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區人類胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東與非洲人胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲人胰島素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球人類胰島素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi SA
  • Biocon Limited
  • Wockhardt Limited
  • Julphar
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • B. Braun Melsungen AG
  • Pfizer Inc.
  • Ypsomed AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4637

The Global Human Insulin Market is projected to expand from USD 24.81 Billion in 2025 to USD 38.31 Billion by 2031, reflecting a compound annual growth rate of 7.51%. This sector covers the commercial environment for biosynthetic peptide hormones that are structurally identical to endogenous insulin, serving as a critical regulation method for blood glucose in patients with diabetes mellitus. The market's upward trajectory is largely fueled by the intensifying global prevalence of diabetes, exacerbated by urbanization, aging populations, and increasing obesity rates which demand consistent therapeutic management. As reported by the International Diabetes Federation in 2024, roughly 589 million adults worldwide were living with diabetes, highlighting an immense patient population requiring effective medical solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 24.81 Billion
Market Size 2031USD 38.31 Billion
CAGR 2026-20317.51%
Fastest Growing SegmentBiosimilar
Largest MarketNorth America

A significant challenge hindering market expansion is the substantial cost associated with manufacturing and distribution, which restricts product affordability in developing nations. These financial obstacles frequently compromise patient adherence and limit market penetration in the very regions experiencing the most rapid rise in disease prevalence. Consequently, strict pricing constraints combined with insufficient reimbursement structures in these areas create a major bottleneck for widespread insulin adoption, thereby curbing potential revenue growth.

Market Driver

Technological advancements in insulin delivery systems are transforming patient care by transitioning preferences from conventional vials and syringes to automated, minimally invasive devices. Innovations including smart insulin pens, tubeless pumps, and closed-loop systems linked with continuous glucose monitors significantly improve glycemic control and treatment adherence. This evolution is driven by the growing demand for advanced platforms that provide precise dosing while minimizing lifestyle disruptions. For example, Insulet Corporation reported in its Third Quarter 2024 Financial Results in November 2024 that revenue for its Omnipod insulin management system rose by approximately 26% year-over-year, supported by robust adoption in both type 1 and type 2 diabetes sectors, demonstrating how these technologies fuel market growth by addressing therapeutic needs.

Simultaneously, the rising adoption of cost-effective biosimilars is altering the competitive landscape by removing economic barriers to access. As patents for major insulin analogs expire, the launch of high-quality biosimilar alternatives provides significant savings for patients and healthcare systems, especially in emerging markets where affordability is paramount. This trend accelerates volume uptake and broadens the treated patient base, as evidenced by Biocon Limited's October 2024 Consolidated Financial Results for Q2 FY25, which showed a 19% year-over-year revenue increase in its biosimilars business on a like-for-like basis. Furthermore, with the International Diabetes Federation estimating global diabetes-related health expenditure to exceed USD 1 trillion in 2024, the urgent need for cost-efficient solutions continues to drive market expansion and sustainable healthcare spending.

Market Challenge

The substantial expense associated with manufacturing and distribution constitutes a major structural impediment to the growth of the Global Human Insulin Market, especially within developing economies. The production of biosynthetic peptide hormones necessitates rigorous quality control and complex, capital-intensive biotechnology facilities, establishing a high baseline cost for the finished product. Additionally, the logistical requirement to maintain a strict cold chain during distribution imposes significant overhead, further increasing the price for end users. In areas with lower average incomes and limited healthcare infrastructure, these cumulative costs make the therapy economically out of reach for a vast segment of the population, effectively limiting market penetration.

This economic disparity severely constrains market potential because the regions with the highest demand growth are often the most financially restricted. According to the International Diabetes Federation, more than 75 percent of adults with diabetes resided in low- and middle-income countries in 2024. This statistic highlights the scale of the difficulty, as the overwhelming majority of the potential patient pool lives in areas where current pricing structures are prohibitive. As a result, the market encounters a significant bottleneck where revenue growth is suppressed by the inability of the primary growth demographic to afford essential treatment.

Market Trends

The introduction of once-weekly basal insulin formulations is fundamentally shifting the treatment paradigm by alleviating the burden associated with daily injection schedules. Pharmaceutical developers are focusing on ultra-long-acting analogs capable of maintaining stable glycemic control for seven days, aiming to reduce injection fatigue and enhance long-term adherence among patients with type 2 diabetes. This innovation addresses lifestyle constraints through chemical structural advancements rather than just device improvements. For instance, Eli Lilly and Company reported in September 2024 from the QWINT-2 phase 3 trial that their once-weekly insulin efsitora alfa achieved non-inferiority to daily insulin degludec, lowering A1C levels by 1.34% compared to 1.26% in insulin-naive adults.

In parallel, the development of non-invasive and oral insulin delivery systems continues to draw substantial investment as companies seek to eliminate the need for subcutaneous administration. This trend involves persistent clinical research into encapsulated oral formulations engineered to survive gastric degradation, providing a needle-free option that could significantly broaden early insulin acceptance. Despite past clinical challenges, pursuit of this technology remains vigorous due to its potential to improve patient convenience and overcome psychological barriers to injectable therapies. Highlighting this ongoing effort, Oramed Pharmaceuticals announced in February 2024 its plans to restart a Phase 3 trial for its oral insulin candidate, ORMD-0801, targeting a specific patient subpopulation that showed significant responsiveness in earlier data analyses.

Key Market Players

  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi S.A.
  • Biocon Limited
  • Wockhardt Limited
  • Julphar
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • B. Braun Melsungen AG
  • Pfizer Inc.
  • Ypsomed AG

Report Scope

In this report, the Global Human Insulin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Insulin Market, By Indication

  • Type I Diabetes
  • Type II Diabetes

Human Insulin Market, By Brand

  • Lantus
  • Humulin R
  • Novolin R
  • Humulin N
  • Exubera
  • Afrezza
  • Novolin N

Human Insulin Market, By Route of Administration

  • Subcutaneous
  • Transdermal
  • Nasal
  • Intravenous
  • Oral
  • Others

Human Insulin Market, By Type

  • Basal
  • Bolus
  • Pre-mixed
  • Biosimilar
  • Traditional

Human Insulin Market, By Onset Time

  • Rapid acting
  • Short-acting
  • Intermediate acting
  • Long acting
  • Pre-Mixed
  • Inhaled
  • Ultra-long Acting

Human Insulin Market, By Products

  • Insulin Pens
  • Insulin Pumps
  • Infusion System
  • Injections

Human Insulin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Insulin Market.

Available Customizations:

Global Human Insulin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Insulin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Type I Diabetes, Type II Diabetes)
    • 5.2.2. By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)
    • 5.2.3. By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral, Others)
    • 5.2.4. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
    • 5.2.5. By Onset Time (Rapid acting, Short-acting, Intermediate acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting)
    • 5.2.6. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections)
    • 5.2.7. By Region
    • 5.2.8. By Company (2025)
  • 5.3. Market Map

6. North America Human Insulin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Brand
    • 6.2.3. By Route of Administration
    • 6.2.4. By Type
    • 6.2.5. By Onset Time
    • 6.2.6. By Products
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Human Insulin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Brand
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Type
        • 6.3.1.2.5. By Onset Time
        • 6.3.1.2.6. By Products
    • 6.3.2. Canada Human Insulin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Brand
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Type
        • 6.3.2.2.5. By Onset Time
        • 6.3.2.2.6. By Products
    • 6.3.3. Mexico Human Insulin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Brand
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Type
        • 6.3.3.2.5. By Onset Time
        • 6.3.3.2.6. By Products

7. Europe Human Insulin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Brand
    • 7.2.3. By Route of Administration
    • 7.2.4. By Type
    • 7.2.5. By Onset Time
    • 7.2.6. By Products
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Human Insulin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Brand
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Type
        • 7.3.1.2.5. By Onset Time
        • 7.3.1.2.6. By Products
    • 7.3.2. France Human Insulin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Brand
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Type
        • 7.3.2.2.5. By Onset Time
        • 7.3.2.2.6. By Products
    • 7.3.3. United Kingdom Human Insulin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Brand
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Type
        • 7.3.3.2.5. By Onset Time
        • 7.3.3.2.6. By Products
    • 7.3.4. Italy Human Insulin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Brand
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Type
        • 7.3.4.2.5. By Onset Time
        • 7.3.4.2.6. By Products
    • 7.3.5. Spain Human Insulin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Brand
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Type
        • 7.3.5.2.5. By Onset Time
        • 7.3.5.2.6. By Products

8. Asia Pacific Human Insulin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Brand
    • 8.2.3. By Route of Administration
    • 8.2.4. By Type
    • 8.2.5. By Onset Time
    • 8.2.6. By Products
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Human Insulin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Brand
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Type
        • 8.3.1.2.5. By Onset Time
        • 8.3.1.2.6. By Products
    • 8.3.2. India Human Insulin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Brand
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Type
        • 8.3.2.2.5. By Onset Time
        • 8.3.2.2.6. By Products
    • 8.3.3. Japan Human Insulin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Brand
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Type
        • 8.3.3.2.5. By Onset Time
        • 8.3.3.2.6. By Products
    • 8.3.4. South Korea Human Insulin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Brand
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Type
        • 8.3.4.2.5. By Onset Time
        • 8.3.4.2.6. By Products
    • 8.3.5. Australia Human Insulin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Brand
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Type
        • 8.3.5.2.5. By Onset Time
        • 8.3.5.2.6. By Products

9. Middle East & Africa Human Insulin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Brand
    • 9.2.3. By Route of Administration
    • 9.2.4. By Type
    • 9.2.5. By Onset Time
    • 9.2.6. By Products
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Human Insulin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Brand
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Type
        • 9.3.1.2.5. By Onset Time
        • 9.3.1.2.6. By Products
    • 9.3.2. UAE Human Insulin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Brand
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Type
        • 9.3.2.2.5. By Onset Time
        • 9.3.2.2.6. By Products
    • 9.3.3. South Africa Human Insulin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Brand
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Type
        • 9.3.3.2.5. By Onset Time
        • 9.3.3.2.6. By Products

10. South America Human Insulin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Brand
    • 10.2.3. By Route of Administration
    • 10.2.4. By Type
    • 10.2.5. By Onset Time
    • 10.2.6. By Products
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Human Insulin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Brand
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Type
        • 10.3.1.2.5. By Onset Time
        • 10.3.1.2.6. By Products
    • 10.3.2. Colombia Human Insulin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Brand
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Type
        • 10.3.2.2.5. By Onset Time
        • 10.3.2.2.6. By Products
    • 10.3.3. Argentina Human Insulin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Brand
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Type
        • 10.3.3.2.5. By Onset Time
        • 10.3.3.2.6. By Products

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Human Insulin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novo Nordisk A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company
  • 15.3. Sanofi S.A.
  • 15.4. Biocon Limited
  • 15.5. Wockhardt Limited
  • 15.6. Julphar
  • 15.7. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 15.8. B. Braun Melsungen AG
  • 15.9. Pfizer Inc.
  • 15.10. Ypsomed AG

16. Strategic Recommendations

17. About Us & Disclaimer